+ Translate

Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways

, : Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. Biochemical Pharmacology 33(19): 3025-3035

We have studied the regulation of human platelet activation by cyclic AMP (cAMP), and the cyclooxygenase products by examining the effect of prostacyclin (PGI2) and indomethacin on platelet aggregation, release reaction and thromboxane B2 (TxB2) generation induced by the full dose range of common platelet agonists in both platelet-rich plasma and washed platelets. Platelet aggregation, [14C]-5HT and TxB2 release induced by "threshold" and "supramaximal" concentrations of ADP, adrenaline, platelet-activating factor (PAF) and U46619 were totally abolished by low concentrations of PGI2 (3-6 nM). In contrast, platelet activation induced by submaximal concentrations of collagen, thrombin and the calcium ionophore A23187 was only partially inhibited by PGI2 (3-3000 nM). PAF-induced release reaction like that induced by ADP and adrenaline was totally dependent on the cyclooxygenase products and aggregation, while U46619-induced release reaction was only partially dependent on aggregation and the cyclooxygenase products. While both PGI2 (18-3000 nM) and indomethacin (10 microM) abolished collagen-induced aggregation and the aggregation-mediated release reaction, neither inhibitor significantly inhibited platelet adhesion or the adhesion-mediated release reaction. Maximal thrombin-induced aggregation and release reaction was also not significantly inhibited by PGI2 (300 nM) or indomethacin (10 microM). Thromboxane (TxB2) generation induced by sub-maximal to maximal concentrations of collagen, thrombin and A23187 was, although significantly inhibited, not abolished by PGI2. These results demonstrate that PAF is a "weak" agonist similar to ADP and adrenaline, U46619 is an agonist intermediate between weak and strong which induces a release reaction that is only partially dependent on aggregation, but unlike the strong agonists, is totally susceptible to inhibition by PGI2, PGI2 is an indirect inhibitor of phospholipase activation, which does not significantly inhibit non-aggregation-mediated arachidonate mobilization, induced by the strong agonists, and the so-called third pathway in the collagen and thrombin-induced release reaction, which is insensitive to indomethacin, is also insensitive to elevators of cAMP such as PGI2.

(PDF 0-2 workdays service)

Accession: 044174500

PMID: 6091666

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Han, E.Hee.; Kim, H.Gyun.; Hwang, Y.Pil.; Choi, J.Ho.; Im, J.Hye.; Park, B.; Yang, J.Hye.; Jeong, T.Cheon.; Jeong, H.Gwang., 2010: The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p'-DDT in human breast cancer cells. o,p'-Dichlorodiphenyltrichloroethane (o,p'-DDT) is a DDT isomer and xenoestrogen that can induce inflammation and cancer. However, the effect of o,p'-DDT on aromatase is unclear. Thus, we investigated the effects of o,p'-DDT on...

Huzoor-Akbar; Witiak, D.T.; Newman, H.A.; Fertel, R.H.; Feller, D.R., 1982: Potentiating effects of clofibrate on prostaglandin-dependent and -independent pathways of human platelet activation: evidence for involvement of cyclic AMP. Although clofibrate has been shown to inhibit platelet aggregation that is caused by thrombin, ADP and epinephrine, by blocking the release of arachidonic acid from platelet phospholipids [8], here we have demonstrated that clofibrate enhanced pla...

Huzoor Akbar D.T.W.; Newman H.A.I.; Fertel R.H.; Feller D.R., 1982: Potentiating effects of clofibrate on prostaglandin dependent and prostaglandin independent pathways of human platelet activation evidence for involvement of cyclic amp. Biochemical Pharmacology 31(11): 2125-2128

Fernandes, A.J.; Lora, M.; Patry, C.; Morisset, S.; Sarrazin, P.; Maciel, F., 1997: Parathyroid hormone induction of cyclooxygenase-2 expression in human osteoblasts depends on both cyclic AMP and calcium-dependent pathways. Advances in Experimental Medicine and Biology 433: 303-306

Rotondo, S.; Krauze-Brzósko, K.; Manarini, S.; Evangelista, V.; Cerletti, C., 2004: Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. 5-Lipoxygenase/cyclooxygenase inhibitors, possessing anti-inflammatory action and gastric safety due to cyclooxygenase-2 and 5-lipoxygenase inhibition and antiplatelet activity due to cyclooxygenase-1 blockade, would be beneficial in the treatment...

Harbon, S.; Leiber, D.; Vesin, M.F., 1983: Phospholipase A2 activation coupled to lipoxygenase and cyclooxygenase pathways in the guinea pig myometrium: interaction with the cyclic AMP and cyclic GMP systems. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 12: 423-428

Frelinger, A.L.; Furman, M.I.; Linden, M.D.; Li, Y.; Fox, M.L.; Barnard, M.R.; Michelson, A.D., 2006: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Thrombotic events still occur in aspirin-treated patients with coronary artery disease. To better understand aspirin "resistance," serum thromboxane B2 (TXB2) and flow cytometric measures of arachidonic acid-induced platelet activation (...

Frelinger, A., L.I.i; Furman, M., I.; Linden, M., D.; Li, Y.; Fox, M., L.; Barnard, M., R.; Michelson, A., D., 2006: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway - A 700-patient study of aspirin resistance. Background-Thrombotic events still occur in aspirin-treated patients with coronary artery disease.Methods and Results-To better understand aspirin "resistance," serum thromboxane B-2 (TXB2) and flow cytometric measures of arachidonic aci...

Smith C.J.; Vasta V.; Degerman E.; Belfrage P.; Manganiello V.C., 1991: Hormone sensitive cyclic gmp inhibited cyclic amp phosphodiesterase in rat adipocytes regulation of insulin dependent and cyclic amp dependent activation by phosphorylation. In 32PO4-labeled adipocytes, isoproterenol (ISO) or physiologically relevant concentrations of insulin rapidly increased phosphorylation of a particulate 135-kDa protein which has been identified as a cGMP-inhibited "low km" cAMP phospho...

Farndale, R.W.; Wong, S.K.F.; Martin, B.R., 1987: Activation of adenylate cyclase in human platelet membranes by guanosine 5' beta gamma imidotriphosphate is inhibited by cyclic amp dependent phosphorylation slow activation occurs in the absence of atp. 1. Incubation of platelet membranes with guanosine 5'-[.beta. .gamma.-imido]triphosphate causes a slow increase in Gs (stimulatory GTP-binding protein) activation of adenylate cyclase. Mg2+ is necessary for this slow activation. 2. This proce...